Patients living with life-limiting rare diseases need access to clinical trials and innovative treatments.

Aparito’s Atom5™ is the solution for improving clinical trials for patients.

Initially designed for paediatric and rare diseases, the platform can enhance compliance and improve the outcomes of any clinical trial.

Our decentralised platform allows for clinical studies to be done anywhere, anytime allowing patients and their caregivers to participate in research from the comfort of their own homes and offers Video Assessments, PROs, Telemedicine, EDC and eConsent, all via one smartphone app.

Available in 193 countries and 125 languages, Atom5™ supports hybrid and decentralised clinical trials and assessments at scale and has transformed clinical trials for sponsors and clinicians all over the world to capture patient data, develop digital endpoints, and streamline the drug development process.

Following another successful year of client growth, team expansion and award wins, we want to celebrate the Aparito team’s hard work and dedication to digitising clinical trials for sponsors, clinicians and patients around the world. We are thrilled to be here at LSE to acknowledge that, and support Stonewall in the process.